Sorafenib inhibits the proliferation and angiogenesis of tumor cells through targeting Raf, VEGF, PDGF receptor tyrosine kinase signaling and downregulating of Ras/MEK/ERK signaling pathway [41, 42]. Here, VEGFA is linked to neoplasm.